KRAS and neoplasm: Similar results were obtained from a large retrospective analysis conducted by Osterlund et al., where peritoneal metastases were reported in 15% of patients with G12C tumor vs 19% of patients with other KRAS mutations (p=0.63) and lung metastases were reported in 39% vs 36%, respectively (p=0.26) (27).